A Phase 2 interventional study of anakinra and pegsunercept in Rheumatoid Arthritis, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-11-26.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Arthritis, Rheumatoid by Amgen — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Amgen.
Among the 57 studies in Arthritis, Rheumatoid by Amgen, this one is one of 3 that started in 2001, is one of 14 in phase 2, and was the 1st registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →1 of the 57 studies in Arthritis, Rheumatoid by Amgen is open now, in 10 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Australia, Belgium and 7 more countries
Ages 18–75
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 17 · Phase 3 17 · Phase 4 12
First in 1997; this study’s year is marked. 3 started in 2001.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 211 across the 47 interventional studies, 2,522 across the 4 observational. Of the 56 that completed or were terminated, 30 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 57 studies in Arthritis, Rheumatoid by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of anakinra (IL-1 ra) and pegsunercept (PEG sTNF-RI) when they are used together in improving the signs and symptoms of rheumatoid arthritis. The study will also evaluate the safety of the combination treatment and its effect on slowing down bone and joint destruction due to rheumatoid arthritis. The results will be compared to the effect when only 1 single medication (anakinra or pegsunercept) is used.
No study locations are listed for this record.
The record gives a start of May 2001 and a completion of Dec 2002. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interleukin 1 Receptor Antagonist Protein